IQWiG states that Lyxumia (Sanofi)has no additional benefit over comparators in the treatment of Type 2 Diabetes
The Institute for Quality and Efficiency in Healthcare (IQWiG) announced that Lyxumia lixisenatide from Sanofi has "no additional benefit" over comparators requested by Germany's Federal Joint Committee (G-BA). Sanofi did not submit data directly comparing the glucagon-like peptide-1 receptor (GLP-1R) agonist to comparators. The Institute said data submitted by the company indirectly comparing Lyxumia with two of the requested comparators -- in combination with metformin vs. sulfonylurea plus metformin, and in combination with basal insulin vs. human insulin -- were not "suitable."
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.